Message from the Chairman
|
Dear Shareholders, MS is a terrible disease affecting more than 2.5 million people worldwide. For the majority of secondary progressive MS patients, there is a lack of approved and effective treatments. While much research is underway, few drug candidates are in late-stage clinical development and the cause and mechanisms of MS are still poorly understood. Against this barren background, BioMS is developing dirucotide, an exciting new MS drug licensed from the University of Alberta in Canada. Dirucotide has demonstrated in clinical trials the potential to delay disease progression in MS patients. Today, we are the only phase III trial for secondary progressive MS in the world. I am proud of the work our company is doing and the progress we have made advancing dirucotide in progressive MS. Our mission remains focused: to deliver an effective and safe treatment for people with this disease. Having witnessed the devastating effects of multiple sclerosis first hand, it is clear to me how large an impact dirucotide will have if we are successful and how critical it is that we succeed.
Clifford Giese, Chairman
|
 |
